Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol

Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol

Abstract Background Benzamide-based radioligands targeting melanin were first developed for imaging melanoma and then for therapeutic purpose with targeted radionuclide therapy (TRT). [131I]ICF01012 presents a highly favorable pharmacokinetics profile in vivo for therapy. Tumour growth reduction and...

Full description

Bibliographic Details
Main Authors: Emilie Thivat, Jacques Rouanet, Philippe Auzeloux, Nicolas Sas, Elodie Jouberton, Sophie Levesque, Tommy Billoux, Sandrine Mansard, Ioana Molnar, Marion Chanchou, Giovanna Fois, Lydia Maigne, Jean-Michel Chezal, Elisabeth Miot-Noirault, Michel D’Incan, Xavier Durando, Florent Cachin
Format: Article
Language:English
Published: BMC 2022-04-01
Series:BMC Cancer
Subjects:
[131I]ICF01012
Targeted radionuclide therapy
Metastatic melanoma
Dosimetry
Online Access:https://doi.org/10.1186/s12885-022-09495-3

Internet

https://doi.org/10.1186/s12885-022-09495-3

Similar Items